Single User License
INR 257837
Site License
INR 515675
Corporate User License
INR 773512

Service Tax Additional

select a format
Price

Single User License
USD 3995
Site License
USD 7990
Corporate User License
USD 11985

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


PharmaLeaders: Mid-Cap Biotechnology Benchmark Report-Sales Forecasts and Product Valuations of Innovative Biotechs

PharmaLeaders: Mid-Cap Biotechnology Benchmark Report-Sales Forecasts and Product Valuations of Innovative Biotechs


  • Products Id :- GDHC006PLR
  • |
  • Pages: 222
  • |
  • March 2015
  • |
  • |
  Request for Sample Report

Executive Summary

PharmaLeaders: Mid-Cap Biotechnology Benchmark Report-Sales Forecasts and Product Valuations of Innovative Biotechs

GlobalData's "PharmaLeaders: Mid-Cap Biotechnology Benchmark Report-Sales Forecasts and Product Valuations of Innovative Biotechs" applies our proprietary ranking methodology to compare the competitive positions of 35 mid-cap biotechnology companies on 14 financial metrics. These companies are analyzed based on their financial performance, research and development (R&D) spending, capital structure, and firm utilization to illustrate the different strategies they are using to increase value for their shareholders and create a competitive advantage. Throughout the report, GlobalData's Industry Dynamics Team provides expert insight, expanding on each of the metrics discussed.

In addition to the financial metrics, this report provides an overview of the biotech sector growth rates, and discusses the regulatory approvals that occurred in 2014, along with our forecast sales outlook for each drug. We also examine how the patent cliff will impact the industry moving forward, along with deals and licensing activity, and the prospects for niche/orphan drugs. Lastly, we use our proprietary database tools to determine the Net Present Value (NPV) of both marketed and clinical pipeline assets and their future profits and cash flows.

Highlights

Key Questions Answered

What specific strategies are these innovative biotech companies employing to gain market share?

What therapeutic areas are these biotech companies focusing their R&D spending?

Which trends will affect the biotech sector moving forward?

How does my pipeline and commercialization strategy match up against the competition?

What specific business development activities are taking place, in terms of partnerships or M&A?

What particular enabling technologies and drug platforms are these biotech companies developing?

How are these biotech companies maximizing their capital spend to gain a competitive advantage?

Scope

This report provides analysis of the key drivers and trends shaping the biotechnology sector; including drivers of financial growth and R&D spending, FDA approvals, generic erosion, corporate strategy, orphan drugs and asset value creation

This report offers a deep dive into the synergies behind partnering and acquisition activity

FDA expedited review-drugs approved by Fast Track, Breakthrough, Priority Review, and Accelerated approval pathways

Six-year forecasts for key drugs approved in 2014; Net Present Value (NPV) for key drugs approved in 2014.

Reasons To Buy

Analyze and track the strategies that these drug companies are using to gain share in the increasingly competitive market

Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending and asset structure

Organize your sales and marketing strategy to identify companies with proprietary technologies in order to maximize opportunities for licensing, partnership, equity investment or takeover

Independent source to benchmark your company's performance against a similar peer group to assess areas of strength/weakness

1 Table of Contents

1 Table of Contents 9

1.1 List of Tables 14

1.2 List of Figures 17

2 Introduction 24

2.1 Report Scope 24

2.2 Companies Covered 25

2.3 Upcoming Reports 26

2.4 Recently Published Reports 26

3 Market Dynamics 27

3.1 Sector Fundamentals 27

3.1.1 Growth Rate 27

3.1.2 R&D Spending 29

3.1.3 Company Outlook 33

3.1.4 Sales Forecasts 36

3.1.5 Product Valuations 39

3.2 FDA Approved 41 New Drugs in 2014 41

3.2.1 Drugs Approved in 2014 43

3.2.2 Multiple Approval Pathways Expedite Review of Innovatie Medicines 46

3.2.3 CDER Continues to Meet PDUFA Goal Dates for Review Cycles 51

3.2.4 GlobalData's Forecast for 2014 Approvals: BMS' Opdivo Projected to be Top Seller 52

3.3 Orphan Drugs: No Longer a Rare Opportunity 54

3.3.1 Historic Number of Orphan Drugs Approved in 2014 56

3.3.2 Orphan Drugs Approved in 2014 56

3.3.3 Celgene's Revlimid Will Eclipse Roche's MabThera/Rituxan by 2018 61

3.4 FDA Approved 27 New Drugs in 2013 62

3.4.1 Drugs Approved in 2013 62

3.4.2 GlobalData's Sales Forecasts for Drugs Approved in 2013 63

3.4.3 NME Approvals Drive Much Needed Value in the Pharmaceutical Market 65

3.4.4 Exceptional Uptake of Sovaldi and Tecfidera Paves the Way for New Optimism in Pharma 67

3.5 Patent Cliff to Erode USD 65 Billion in Sales by 2019 71

3.5.1 Top Patent Expiries 72

4 Collaboration and Acquisition Strategies 76

4.1 Deals Landscape 76

4.1.1 Overview 76

4.1.2 Therapeutic Analysis 79

4.2 M&A Analysis 82

4.2.1 Overview 82

4.2.2 Top Spenders 86

4.3 Licensing and Partnership Deals 94

4.3.1 Overview 94

4.3.2 Top Spenders 99

5 Financial Management 110

5.1 Revenue 111

5.1.1 Regeneron, Actelion, and Alexion 111

5.2 Year-to-Year Revenue Growth 113

5.2.1 Peer Group Leaders 113

5.2.2 Theravance and Vertex 115

5.3 Operating Income 116

5.3.1 Regeneron, Jazz, and Salix 116

5.3.2 Ironwood 118

5.4 Gross Profit Margin 118

5.4.1 Peer Group Leaders 118

5.5 Expense Performance Metrics 120

5.5.1 R&D Spending 120

5.5.2 R&D Spending Growth 122

5.5.3 SG&A Margin 124

5.6 Liquidity and Valuation Metrics 125

5.6.1 Capital Expenditures 125

5.6.2 Cash and Marketable Securities 127

5.6.3 Total Debt 128

5.6.4 Total Assets 130

5.6.5 Cash Ratio 131

5.6.6 Market Capitalization 132

5.6.7 Enterprise Value 133

6 Company Analysis 135

6.1 Acadia 135

6.1.1 Marketed Products 135

6.1.2 Nuplazid Sales Forecast 138

6.1.3 Nuplazid NPV & DCF 138

6.1.4 Clinical Pipeline 140

6.2 Actelion 143

6.2.1 Marketed Products 143

6.2.2 Opsumit and Tracleer Sales Forecasts 146

6.2.3 Opsumit NPV & DCF 147

6.2.4 Clinical Pipeline 148

6.3 Alexion 151

6.3.1 Marketed Products 151

6.3.2 Soliris Sales Forecast 154

6.3.3 Soliris NPV & DCF 155

6.3.4 Clinical Pipeline 156

6.4 BioMarin 159

6.4.1 Marketed Products 159

6.4.2 Naglazyme and BioMarin Sales Forecasts 161

6.4.3 Naglazyme NPV & DCF 162

6.4.4 Clinical Pipeline 164

6.5 Cubist 167

6.5.1 Marketed Products 167

6.5.2 Cubicin Sales Forecast 169

6.5.3 Cubicin NPV & DCF 171

6.5.4 Clinical Pipeline 172

6.6 Incyte 175

6.6.1 Marketed Products 175

6.6.2 Jakafi Sales Forecast 178

6.6.3 Jakafi NPV & DCF 178

6.6.4 Clinical Pipeline 179

6.7 Medivation 183

6.7.1 Marketed Products 183

6.7.2 Xtandi Sales Forecast 186

6.7.3 Xtandi NPV & DCF 186

6.7.4 Clinical Pipeline 188

6.8 Pharmacyclics 191

6.8.1 Marketed Products 191

6.8.2 Imbruvica Sales Forecast 194

6.8.3 Imbruvica NPV & DCF 194

6.8.4 Clinical Pipeline 196

6.9 Regeneron 199

6.9.1 Marketed Products 199

6.9.2 Eylea Sales Forecast 202

6.9.3 Eylea NPV & DCF 203

6.9.4 Clinical Pipeline 204

6.10 Vertex 208

6.10.1 Marketed Products 208

6.10.2 Kalydeco Sales Forecast 211

6.10.3 Kalydeco NPV & DCF 211

6.10.4 Clinical Pipeline 213

7 Future Outlook 216

8 Appendix 218

8.1 Research Methodology 218

8.1.1 Coverage 218

8.1.2 Secondary Research 218

8.2 About the Author 219

8.2.1 Adam Dion, Industry Analyst 219

8.3 Director, Healthcare Industry Dynamics 220

8.4 Global Head of Healthcare 220

8.5 About the Industry Dynamics Team 220

8.6 About GlobalData 221

8.7 Disclosure Information 221

8.8 Disclaimer 221

1.2 List of Figures

Figure 1: Mid-Cap Biotech Peer Group, Revenue (USD m) and Growth Rate, 2009-2013 28

Figure 2: Mid-Cap Biotech Peer Group, Revenue (USD m) and Average Gross Margin, 2008-2013 29

Figure 3: Mid-Cap Biotech Peer Group, R&D Spending (USD m) and Growth Rate 2009-2013 30

Figure 4: Global Marketed Product and Pipeline Sales (USD m) Contributions, 2019 32

Figure 5: Total Pharmaceutical Market Pipeline Revenue (USD m), 2014-2019 33

Figure 6: Mid-Cap Biotech Peer Group, Company Sales (USD m), 2013 vs. 2019 34

Figure 7: Mid-Cap Biotech Peer Group, Product Forecasts (USD m), 2019 37

Figure 8: Mid-Cap Biotech Peer Group, Leading Products, NPV (USD m) 40

Figure 9: Number of NMEs Filed With and Approved by the CDER, 2004-2014 42

Figure 10: Number of BLAs Approved by CDER, 2004-2014 43

Figure 11: CDER Median Total Time (Months) to Drug Approval, Priority Review, 1993-2014 46

Figure 12: Status of CDER Breakthrough Therapy Requests, 2014 48

Figure 13: Percentage of Total Breakthrough Therapy Requests By Therapeutic Area, 2014 49

Figure 14: Percentage of Total Breakthrough Therapy Approvals By Therapeutic Area, 2014 49

Figure 15: Percentage of Total NMEs Approved by the CDER by Pathway, 2011-2014 51

Figure 16: Percentage of Total NMEs Approved During the First Review Cycle and First in the US, 2011-2014 52

Figure 17: Net Present Value (USD m) for Key Approvals, 2014 54

Figure 18: Number of Orphan Drugs Approved, 1983-2014 56

Figure 19: Orphan Drug Peer Group Forecast (USD m), 2009-2019 58

Figure 20: Leading Orphan Drug Sales (USD m), Top 25, 2019 59

Figure 21: Leading Orphan Drug Sales (USD m), Cont'd, 2019 60

Figure 22: Revlimid vs. MabThera/Rituxan Sales (USD m), 2006-2019 61

Figure 23: Combined Revenue (USD m) Projections for 2013 vs. 2012 FDA Approvals, 2012-2019 65

Figure 24: First Full-Year Sales (USD m) for Major Product Launches by Year, 2009-2013 66

Figure 25: Revenue (USD m) Projections for 2013 FDA Approvals, 2014-2019 68

Figure 26: Patent Cliff Sales (USD m) Erosion, 2013-2019 72

Figure 27: Biotechnology Sector, Total M&As and Licensing Deals and Deal Values (USD m), 2009-2014 77

Figure 28: Biotechnology Sector, Total and Average Milestone Payments (USD m), 2010-2014 78

Figure 29: Biotechnology Sector, Total and Average Upfront Payments (USD m), 2010-2014 79

Figure 30: Biotechnology Sector, Total Number of Deals by Therapy Area, 2010-2014 80

Figure 31: Biotechnology Sector, Distribution (%) of Deals by Therapy Area, 2010-2014 81

Figure 32: Biotechnology Sector, Total Deal Value (USD m) by Therapy Area, 2010-2014 82

Figure 33: Biotechnology Sector, Number of M&A Deals and Deal Values (USD m), 2009-2014 83

Figure 34: Biotechnology Sector, M&A Deal Values (USD m) by Company, 2010-2014 86

Figure 35: Biotechnology Sector, Total Number of Licensing Deals and Deal Values (USD m), 2009-2014 94

Figure 36: Biotechnology Sector, Licensing and Partnership Deal Values (USD m) by Company, 2010-2014 99

Figure 37: Revenue (USD m) by Company, 2013 112

Figure 38: Revenue Growth (%) by Company, 2013 115

Figure 39: Operating Income (USD m) by Company, 2013 117

Figure 40: Gross Profit Margin (%) by Company, 2013 119

Figure 41: R&D Spending (USD m) by Company, 2013 121

Figure 42: R&D Spending Growth (%) By Company, 2013 123

Figure 43: SG&A Spending (%) of Revenue by Company, 2013 125

Figure 44: Capex (USD m) by Company, 2013 126

Figure 45: Cash and Marketable Securities (USD m) by Company, 2013 128

Figure 46: Total Debt (USD m) by Company, 2013 129

Figure 47: Total Assets (USD m) by Company, 2013 131

Figure 48: Cash Ratio (%) by Company, 2013 132

Figure 49: Market Capitalization (USD m) by Company 133

Figure 50: Enterprise Value (USD m) by Company 134

Figure 51: Nuplazid Sales Forecast (USD m), 2015-2019 138

Figure 52: Nuplazid Net Present Value (USD m) 139

Figure 53: Nuplazid Net Profit and DCF (USD m), 2015-2029 139

Figure 54: Acadia, Number of Pipeline Products vs. Number of Clinical Trials 140

Figure 55: Nuplazid, Number of Clinical Trials 140

Figure 56: Acadia, Number of Clinical Trials in Late-Stage by Therapy Area 141

Figure 57: Acadia, Percentage of Late-Stage Pipeline 141

Figure 58: Acadia, Number of Clinical Trials by Phase 142

Figure 59: Acadia, Number of Clinical Trials by Indication, CNS Disorders 142

Figure 60: Opsumit and Tracleer Sales Forecasts (USD m), 2006-2019 146

Figure 61: Actelion Total Revenue and Forecast (USD m), 2006-2019 146

Figure 62: Opsumit, Net Present Value (USD m) 147

Figure 63: Opsumit, Net Profit and DCF (USD m), 2014-2029 148

Figure 64: Actelion, Number of Pipeline Products vs. Number of Clinical Trials 148

Figure 65: Actelion, Number of Clinical Trials 149

Figure 66: Actelion, Number of Clinical Trials in Late-Stage by Therapy Area 149

Figure 67: Actelion, Percentage of Late-Stage Pipeline 150

Figure 68: Actelion, Number of Clinical Trials by Phase 150

Figure 69: Actelion, Number of Clinical Trials by Indication, Cardiovascular Disorders 151

Figure 70: Soliris Sales Forecast (USD m), 2007-2019 154

Figure 71: Alexion, Revenue and Forecast (USD m), 2009-2019 155

Figure 72: Soliris, Net Present Value (USD m) 156

Figure 73: Soliris, Net Profit and DCF (USD m), 2014-2029 156

Figure 74: Alexion, Number of Pipeline Products vs. Number of Clinical Trials 157

Figure 75: Soliris, Number of Clinical Trials 157

Figure 76: Alexion, Number of Clinical Trials in Late-Stage by Therapy Area 158

Figure 77: Alexion, Percentage of Late-Stage Pipeline 158

Figure 78: Alexion, Number of Clinical Trials by Phase 159

Figure 79: Naglazyme Sales Forecast (USD m), 2008-2019 161

Figure 80: BioMarin Total Revenue and Forecast (USD m), 2008-2019 162

Figure 81: Naglazyme, NPV (USD m) 163

Figure 82: Naglazyme, Net Profit and DCF (USD m), 2014-2029 163

Figure 83: BioMarin, Number of Pipeline Products vs. Number of Clinical Trials 164

Figure 84: BioMarin, Marketed Products Clinical Trials 164

Figure 85: BioMarin, Number of Clinical Trials by Therapy Area 165

Figure 86: BioMarin, Percentage of Late-Stage Pipeline 165

Figure 87: BioMarin, Number of Clinical Trials by Phase 166

Figure 88: BioMarin, Number of Clinical Trials by Indication, Metabolic Disorders 166

Figure 89: Cubicin Sales Forecast (USD m), 2008-2019 170

Figure 90: Cubist Revenue and Forecast (USD m), 2008-2019 170

Figure 91: Cubicin NPV (USD m) 171

Figure 92: Cubicin Net Profit and DCF (USD m), 2014-2022 172

Figure 93: Cubist, Number of Pipeline Products vs. Number of Clinical Trials 172

Figure 94: Cubist, Marketed Products Clinical Trials 173

Figure 95: Cubist, Percentage of Late-Stage Pipeline 173

Figure 96: Cubist, Number of Clinical Trials in Late-Stage by Therapy Area 174

Figure 97: Cubist, Number of Clinical Trials by Phase 174

Figure 98: Cubist, Number of Clinical Trials by Indication, Infectious Diseases 175

Figure 99: Jakafi Sales Forecast (USD m), 2012-2019 178

Figure 100: Jakafi NPV (USD m) 179

Figure 101: Jakafi, Net Profit and DCF (USD m), 2014-2029 179

Figure 102: Incyte, Number of Pipeline Products vs. Number of Clinical Trials 180

Figure 103: Incyte, Marketed Products Clinical Trials 180

Figure 104: Incyte, Number of Clinical Trials in Late-Stage by Therapy Area 181

Figure 105: Incyte, Percentage of Late-Stage Pipeline 181

Figure 106: Incyte, Number of Clinical Trials by Phase 182

Figure 107: Incyte, Number of Clinical Trials in Late-Stage by Indication, Hematology 182

Figure 108: Xtandi Sales Forecast (USD m), 2012-2019 186

Figure 109: Xtandi NPV (USD m) 187

Figure 110: Xtandi Net Profit and DCF (USD m), 2014-2029 187

Figure 111: Medivation, Number of Pipeline Products vs. Number of Clinical Trials 188

Figure 112: Medivation, Marketed Products Clinical Trials 188

Figure 113: Medivation, Percentage of Late-Stage Pipeline 189

Figure 114: Medivation, Number of Clinical Trials in Late-Stage by Therapy Area 189

Figure 115: Medivation, Number of Clinical Trials by Phase 190

Figure 116: Medivation, Number of Clinical Trials in Late-Stage by Indication, Oncology and CNS 190

Figure 117: Imbruvica Sales Forecast (USD m), 2013-2019 194

Figure 118: Imbruvica NPV (USD m) 195

Figure 119: Imbruvica Net Profit and DCF (USD m), 2014-2029 195

Figure 120: Pharmacyclics, Number of Pipeline Products vs. Number of Clinical Trials 196

Figure 121: Pharmacyclics, Marketed Products Clinical Trials 196

Figure 122: Pharmacyclics, Percentage of Late-Stage Pipeline 197

Figure 123: Pharmacyclics, Number of Clinical Trials in Late-Stage by Therapy Area 197

Figure 124: Pharmacyclics, Number of Clinical Trials by Phase 198

Figure 125: Pharmacyclics, Number of Clinical Trials in Late-Stage by Indication, Oncology 198

Figure 126: Eylea Sales Forecast (USD m), 2012-2019 202

Figure 127: Regeneron Revenue Forecast (USD m), 2012-2019 202

Figure 128: Eylea NPV (USD m), 203

Figure 129: Eylea Net Profit and DCF (USD m), 2014-2029 204

Figure 130: Regeneron, Number of Pipeline Products vs. Number of Clinical Trials 205

Figure 131: Regeneron, Marketed Products Clinical Trials 205

Figure 132: Regeneron, Percentage of Late-Stage Pipeline 206

Figure 133: Regeneron, Number of Clinical Trials in Late-Stage by Therapy Area 206

Figure 134: Regeneron, Number of Clinical Trials by Phase 207

Figure 135: Regeneron, Number of Clinical Trials by Indication, Ophthalmology 207

Figure 136: Regeneron, Selected Product NPVs 208

Figure 137: Kalydeco Sales Forecast (USD m), 2012-2019 211

Figure 138: Kalydeco NPV (USD m) 212

Figure 139: Kalydeco, Net Profit and DCF (USD m), 2014-2029 212

Figure 140: Vertex, Number of Pipeline Products vs. Number of Clinical Trials 213

Figure 141: Vertex, Marketed Products Clinical Trials 213

Figure 142: Vertex, Percentage of Late-Stage Pipeline 214

Figure 143: Vertex, Number of Clinical Trials in Late-Stage by Therapy Area 214

Figure 144: Vertex, Number of Clinical Trials by Phase 215

Figure 145: Vertex, Number of Clinical Trials in Late-Stage by Indication 215

1.1 List of Tables

Table 1: Pharmaceutical Industry, Sector Revenues (USD bn) and CAGRs, 2011-2019 31

Table 2: Pharmaceutical Industry, Sector R&D Spending (USD bn), 2008-2013 31

Table 3: Biotech Peer Group, Company Forecasts (USD m), 2014-2019 35

Table 4: Biotech Peer Group, Product Forecasts (USD m), 2013-2019 38

Table 5: NMEs Approved By the CDER, 2014 44

Table 6: Sales Forecasts (USD m) for Key NME Approvals in 2014, 2014-2019 53

Table 7: Orphan Drug Approvals, 2014 57

Table 8: NMEs Approved in 2013 62

Table 9: Sales Forecasts (USD m) for Key NME Approvals in 2013, 2014-2019 64

Table 10: Top Patent Expiries, Sales (USD m), 2013-2019 73

Table 11: Biotechnology Sector, Headline M&A Deals, 2014 84

Table 12: Biotechnology Sector, Headline M&A Deals, 2013 85

Table 13: Salix, M&A Deals, Summary, 2005-2014 87

Table 14: Salix, M&A Deals, Financials, 2005-2014 87

Table 15: Sumitomo Dainnipon, M&A Deals, Summary, 2009-2014 88

Table 16: Sumitomo Dainippon, M&A Deals, Financials, 2009-2014 88

Table 17: Jazz, M&A Deals, Summary, 2011-2014 90

Table 18: Jazz, M&A Deals, Financials, 2011-2014 91

Table 19: Cubist, M&A Deals, Summary, 2009-2014 92

Table 20: Cubist, M&A Deals, Financials, 2007-2014 92

Table 21: Alexion, M&A Deals, Summary, 2008-2014 93

Table 22: Alexion, M&A Deals, Financials, 2006-2014 94

Table 23: Biotechnology Sector, Headline Licensing and Partnership Deals, 2014 95

Table 24: Biotechnology Sector, Headline Licensing and Partnership Deals, 2014 (Cont'd) 97

Table 25: Biotechnology Sector, Headline Licensing and Partnership Deals, 2013 98

Table 26: H. Lundbeck, Licensing Deals, Summary, 2008-2014 100

Table 27: H. Lundbeck, Licensing Deals, Financials, 2008-2014 101

Table 28: Isis, Licensing Deals, Summary, 2008-2014 102

Table 29: Isis, Licensing Deals, Financials, 2008-2014 103

Table 30: Seattle Genetics, Licensing Deals, Summary, 2009-2014 104

Table 31: Seattle Genetics, Licensing Deals, Financials, 2007-2014 105

Table 32: Alnylam, Licensing Deals, Summary, 2007-2014 106

Table 33: Alnylam, Licensing Deals, Financials, 2007-2014 107

Table 34: Regeneron, Licensing Deals, Summary, 2006-2014 108

Table 35: Regeneron, Licensing Deals, Financials, 2005-2014 109

Table 36: Acadia, Marketed Product Overview 135

Table 37: Nuplazid, Product Details 136

Table 38: Nuplazid, Milestone Details, 2012-2014 137

Table 39: Nuplazid, NPV Parameters 138

Table 40: Actelion, Marketed Products Overview 143

Table 41: Opsumit, Product Details 144

Table 42: Opsumit, Milestone Details, 2013-2014 145

Table 43: Opsumit, NPV Parameters 147

Table 44: Alexion, Marketed Product Overview 151

Table 45: Soliris, Product Details 152

Table 46: Soliris, Milestone Details, 2014 153

Table 47: Soliris, NPV Parameters 155

Table 48: BioMarin, Marketed Products Overview 160

Table 49: Naglazyme, Product Details 160

Table 50: Naglazyme, Milestone Details, 2005-2009 161

Table 51: Naglazyme, NPV Parameters 162

Table 52: Cubist, Marketed Products Overview 167

Table 53: Cubicin, Product Details 168

Table 54: Cubicin, Milestone Details, 2011-2014 169

Table 55: Cubicin, NPV Parameters 171

Table 56: Incyte, Marketed Product Overview 176

Table 57: Jakafi, Product Details 176

Table 58: Jakafi, Milestone Details, 2014 177

Table 59: Jakafi, NPV Parameters 178

Table 60: Medivation, Marketed Product Overview 183

Table 61: Xtandi, Product Details 184

Table 62: Xtandi, Milestone Details, 2014 185

Table 63: Xtandi, NPV Parameters 186

Table 64: Pharmacyclics, Marketed Product Overview 191

Table 65: Imbruvica, Product Details 192

Table 66: Imbruvica, Milestone Details, 2014 193

Table 67: Imbruvica, NPV Parameters 194

Table 68: Regeneron, Marketed Products Overview 199

Table 69: Eylea, Product Details 200

Table 70: Eylea, Milestone Details, 2014 201

Table 71: Eylea, NPV Parameters 203

Table 72: Vertex, Marketed Products Overview 209

Table 73: Kalydeco, Product Details 209

Table 74: Kalydeco, Milestone Details, 2013-2014 210

Table 75: Kalydeco, NPV Parameters 211

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com